- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00836394
Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis (WBV-JIA)
The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project aims to evaluate the effect of a therapy called whole body vibration (WBV) on muscle function and joint biomechanics in children and adolescents suffering from juvenile idiopathic arthritis (JIA).
JIA is the most common chronic form of arthritis in children and affects at least 1 in 1000 Canadian children and youth. Current data suggests that a large number of children suffering from JIA will encounter permanent joint damage, to which direct effects of inflammation are an important contributor. Nevertheless, recent research has also shown that impaired muscle function and a subsequent alteration of joint loading might by itself induce joint damage. Fifty percent of JIA patients have significant impairments of muscle function and this is often present in patients who do not have active arthritis anymore. In addition to optimum medical treatment of the disease, it is therefore important to improve muscle function in order to protect the joints.
WBV therapy might be an interesting technique to achieve this in JIA patients. It is able to improve muscle function very efficiently with relatively short training times and at the same time confers loads to the lower limbs which are only 30% of body weight. The WBV device consists of a plate going up and down along a fulcrum at a high frequency. The patient stands on the WBV device and the vibration will induce muscle stretch reflexes producing muscle contractions. These muscle contractions are similar to muscle activity during exercise and are not perceived as painful or unpleasant. The technique has been used in children with several conditions impairing muscle function.
The primary question to be investigated in the proposed study is whether WBV therapy will significantly improve muscle function in JIA patients. In addition, the effect of an improvement in muscle function on gait and the loading of individual joints at the lower extremity will be examined. Finally the effect of WBV therapy on quality of life will be assessed.
We propose conducting a controlled trial investigation. This implies, that one group of study participants, called the intervention group, will do the WBV therapy, whereas a second group, called the control group, will just follow their daily habitual activities. All participants will have an initial assessment of muscle function, electrical muscle activity and joint biomechanics by completely painless measurement techniques at the Children's Hospital of Eastern Ontario (CHEO) and a nearby Human Motion Biomechanics lab at the University of Ottawa. In addition, an MRI of the lower legs without contrast media will be done to confirm the absence of joint effusions as well as bone or muscle edema. Quality of life will be assessed by a standard questionnaire that has been validated in JIA. Subsequently, study participants in the intervention group as well as their parents will be introduced to the therapy during two separate sessions at the CHEO. They will then take a WBV device home and perform 6 minutes of training on 5 days a week for 3 months. Each month, they will return to CHEO for assessment of muscle function and demonstration of training technique. At the end of the 3 month period, both intervention and control group patients will repeat the initial set of assessments including MRI. After another 3 month period, all participants will return for a final assessment of muscle function and joint biomechanics but not MRI to document persistence of any change observed.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K0C 1L0
- Children's Hospital of Eastern Ontario
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of JIA
- No active lower-limb arthritis at recruitment shown by clinical examination or MRI
- No active arthritis in the 3 months prior to study entry
- Age > 7 years and < 18 years
- Written informed consent from parents and patients over 14 years of age, assent from children 7 to 14 years
- Written commitment by parents to supervise each therapy session
- Z-score power ≤ -1 as determined on the Leonardo force plate
Exclusion Criteria:
- Lower-limb arthritis on clinical examination or MRI
- Acute venous thrombosis
- Acute hernia
- Migraine
- Epilepsy
- Pregnancy
- Participation in another interventional study
- Surgery and/or fracture within previous 3 months
- Joint replacements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Group
Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
|
6 minutes of training on 5 days a week for 3 months
Other Names:
|
No Intervention: Control
Will follow daily habitual activities
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective is to evaluate the effect of whole body vibration therapy on muscle function by measuring the increase in z-score muscle power during a two leg jump as determined by jumping mechanography after 12 weeks compared to baseline.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The increase in muscle force measured during a one leg jump as determined by jumping mechanography
Time Frame: 12 weeks
|
12 weeks
|
The increase in joint moment and power of the lower-limb measured in a gait lab using motion analysis
Time Frame: 12 weeks
|
12 weeks
|
The change in range of motion, velocity and step distance during walking measured by motion analysis and on the Leonardo gangway
Time Frame: 12 weeks
|
12 weeks
|
Muscle activation changes in amplitude and frequency content measured by surface EMG
Time Frame: 12 weeks
|
12 weeks
|
The safety of the therapy by documenting any recurrence of joint effusions, bone marrow or muscle edema as determined by MRI imaging of the lower extremity
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Johannes Roth, MD, Children's Hospital of Eastern Ontario
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WBV-JIA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Juvenile Idiopathic Arthritis
-
University of AarhusAarhus University HospitalCompletedPolyarticular Juvenile Rheumatoid Arthritis | Systemic Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis, OligoarthritisDenmark
-
Institut National de la Santé Et de la Recherche...CompletedSystemic-Onset Juvenile Idiopathic ArthritisFrance
-
GeneScience Pharmaceuticals Co., Ltd.Not yet recruitingActive Systemic Juvenile Idiopathic ArthritisChina
-
Novartis PharmaceuticalsCompletedSystemic Juvenile Idiopathic Arthritis (SJIA)Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
-
Novartis PharmaceuticalsPediatric Rheumatology International Trials OrganizationCompletedSystemic Juvenile Idiopathic Arthritis With Active FlareUnited States, Argentina, Canada, Switzerland, Germany, Israel, South Africa, Belgium, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru
-
University of British ColumbiaUniversity of Manitoba; The Hospital for Sick Children; McGill University Health... and other collaboratorsRecruiting
-
AbbVieCompletedPolyarticular Juvenile Idiopathic Arthritis
-
NovartisCompletedArthritis, Juvenile RheumatoidItaly
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile Idiopathic Arthritis (JIA)France
Clinical Trials on Galileo (whole body vibration (WBV) therapy)
-
University of StrathclydeQueen Elizabeth National Spinal Injuries Unit, GlasgowUnknownOsteoporosis | Spinal Cord InjuryUnited Kingdom
-
Ludwig-Maximilians - University of MunichMedical University InnsbruckUnknownPostural Control | Subjective Instablity
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Chemotherapy-Induced Peripheral NeuropathyUnited States
-
University of CologneCompleted
-
University Hospital Inselspital, BerneBern University of Applied SciencesTerminated
-
Schön Klinik Berchtesgadener LandCompletedChronic Obstructive Pulmonary DiseaseGermany
-
Universidad Rey Juan CarlosCompleted
-
University of HailNot yet recruiting
-
Heidelberg UniversityNational Center for Tumor Diseases, HeidelbergCompleted
-
University Children's Hospital, ZurichUnknownIncontinence, UrinarySwitzerland